[ad_1]
NEW YORK, February 24, 2021 / PRNewswire / – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current therapeutics to treat and prevent Alzheimer’s disease. Hoth has also obtained an exclusive license agreement for the use of this drug for other indications.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with the destruction of higher brain structures, such as those involved in memory and cognition. The disease causes deficits in cognitive function and a decrease in memory, learning, language and the ability to make intentional and determined movements. The disease is expected to triple at least three times between 2000 and 2050, making AD a global public health problem.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients with indications such as atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth also recently entered into two different deals to further develop two different potential vaccines to prevent or treat COVID-19. For more information, visit https://ir.hoththerapeutics.com/.
Forward-looking statement
This press release includes forward-looking statements based on Hoth’s current expectations that may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. , and are subject to significant risks, uncertainties and assumptions. These statements relate to Hoth’s business strategies; timing of regulatory submissions; the ability to obtain and maintain regulatory approval for existing product candidates and any other product candidates that we may develop, and labeling under any approval we may obtain; the schedule and costs of clinical trials, the schedule and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, clinical trials, research programs, health systems, or the global economy as a whole; our intellectual property; our dependence on third party organizations; our competitive position; our industrial environment; our expected financial and operating results, including expected sources of revenue; our assumptions regarding the size of the available market, the benefits of our products, the prices of the products, the timing of the launch of the products; management’s expectations regarding future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash flow requirements and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by these forward-looking statements. You should not rely on these forward-looking statements, which include words such as “might”, “believe”, “expect”, “intend”, “estimate”, “expect”, “may”, “Continue” predict, “” potential “,” project “or similar terms, variations of these terms or the negative of these terms. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee such results. Hoth may not achieve its expectations and beliefs may not prove to be correct. Actual results may differ materially from those indicated by these forward-looking statements due to various important factors, including, without limitation , market conditions and the factors described in the section entitled “Risk Factors” of Hoth’s latest annual report on Form 10 – Other Filings by K and Hoth with the US Securities and Exchange Commission All such statements are not valid only on the date of their presentation. Therefore, forward-looking statements should be viewed only as Hoth’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, activity levels, performance or achievements. Hoth does not undertake and specifically disclaims any obligation to update, republish or revise forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unforeseen events, except as required by law applicable requires it.
Investor contact:
LR Advisors LLC
E-mail: [email protected]
www.hoththerapeutics.com
Telephone: (678) 570-6791
SOURCE Hoth Therapeutics, Inc.
Related links
https://ir.hoththerapeutics.com
Source link
